Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Olink Holding AB (publ) OLK NASDAQ

NASDAQ Global Market • Healthcare • Medical - Diagnostics & Research • SE • USD

SharesGrow Score
32/100
0/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$21.50
-17.6%

Olink Holding AB (publ) (OLK) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $26.08. It has a SharesGrow Score of 32/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Analyst consensus target is OLK = $22 (-17.6% upside).

Financials: revenue is $170M, +48.1%/yr average growth. Net income is $32M (loss), growing at -181.8%/yr. Net profit margin is -18.6% (negative). Gross margin is 58.2% (-9.5 pp trend).

Balance sheet: total debt is $27M against $503M equity (Debt-to-Equity (D/E) ratio 0.05, conservative). Current ratio is 4.75 (strong liquidity). Debt-to-assets is 4.4%. Total assets: $602M.

Analyst outlook: 2 / 6 analysts rate OLK as buy (33%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 20/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 55/100 (Partial), Future 16/100 (Fail), Income 10/100 (Fail).

$21.50
▼ 17.56% Downside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Olink Holding AB (publ), the average price target is $21.50, with a high forecast of $27.00, and a low forecast of $16.00.
Highest Price Target
$27.00
Average Price Target
$21.50
Lowest Price Target
$16.00

OLK SharesGrow Score Overview

38/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 20/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 55/100
Gross margin is + market cap
FUTURE 16/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — OLK

✗
VALUE Fail
20/100
OLK trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $22, implying -15.6% from the current price $26. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
OLK: +48.1%/yr revenue is, -181.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet OLK: Debt-to-Equity (D/E) ratio 0.05 (conservative), Current ratio is 4.75 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
55/100
OLK: Gross margin is 58.2% (-9.5 pp trend), $3B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 55/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
16/100
Analyst outlook: 2 / 6 analysts rate OLK as buy (33%). Analyst consensus target is $22 (-15.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
OLK: Net profit margin is -18.6%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range14.1-26.09
Volume1.89M
Avg Volume (30D)545.96K
Market Cap$3.24B
Beta (1Y)0.52
Share Statistics
EPS (TTM)-0.26
Shares Outstanding$124M
IPO Date2021-03-26
Employees707
CEOJon Heimer
Financial Highlights & Ratios
Revenue (TTM)$169.91M
Gross Profit$98.87M
EBITDA$-30.91M
Net Income$-31.66M
Operating Income$-49.94M
Total Cash$120.96M
Total Debt$26.79M
Net Debt$-94.17M
Total Assets$602.27M
Price / Earnings (P/E)-100.3
Price / Sales (P/S)19.09
Analyst Forecast
1Y Price Target$21.50
Target High$27.00
Target Low$16.00
Upside-17.6%
Rating ConsensusHold
Analysts Covering6
Buy 33% Hold 67% Sell 0%
Company Info
CountrySE
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS6807101000

Price Chart

Track all markets on TradingView
OLK
Olink Holding AB (publ) ↗  ·  NASDAQ Global Market
Healthcare • Medical - Diagnostics & Research
14.10 52WK RANGE 26.09

People Also View

QGEN
QGEN
Qiagen N.V.
$41.76
-0.36%
 SYNH
SYNH
Syneos Health, Inc.
$42.98
+0.02%
 NEOG
NEOG
Neogen Corporation
$9.61
+5.14%
 CSTL
CSTL
Castle Biosciences, Inc.
$24.37
+3.57%
 ACRS
ACRS
Aclaris Therapeutics, Inc.
$3.92
+0.51%
 GTH
GTH
Genetron Holdings Limited
$4.03
+0.12%
 FONR
FONR
FONAR Corporation
$18.76
+0.27%
 STIM
STIM
Neuronetics, Inc.
$1.43
+2.88%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message